Latest news with #ThermoScientific
Associated Press
3 days ago
- Health
- Associated Press
Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer's new Proteograph ONE Assay to accelerate analysis and reduce costs, making large-scale studies feasible REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, and Korea University, a leading research institution committed to innovation and global impact, today announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes. Seer's latest platform advances will allow deep, unbiased proteomic analysis of 20,000 plasma samples in less time and cost than has ever before been possible. These will include samples from 15,000 cancer patients and 5,000 healthy patients that will serve as controls, sourced from Korea's leading cancer institutions: Seoul National University Hospital, the National Cancer Center, and Samsung Medical Center. The three-year study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea, which supports ambitious, high-impact health research. 'We carefully evaluated multiple approaches to expand the dynamic range of the plasma proteome—including some attempting to replicate Seer's Proteograph platform—and Seer's assay stood out as the only solution capable of delivering the depth, scale, and, critically, reproducibility needed for this ambitious study,' said Professor Sang-Won Lee at the Center of Proteogenome Research (CPGR) of Korea University. 'The unique combination of Seer's latest platform and CPGR's proprietary dual online liquid chromatography technology gives us the ability to conduct population-scale research that would otherwise be prohibitively complex and slow. This collaboration represents a major step toward developing AI-powered diagnostics that could fundamentally improve how we detect and treat cancer in younger adults.' By leveraging the power of deep proteomic analysis, this study aims to catalyze a new wave of diagnostics that are more sensitive, scalable, and personalized—ultimately driving earlier interventions and improving survival outcomes in young adult cancer patients worldwide. Transformational Technology for Population-Scale Proteomics At the heart of the study is Seer's Proteograph ONE workflow, introduced this week at the 2025 American Society for Mass Spectrometry (ASMS) Conference in Baltimore, MD. The next-generation system dramatically increases scale and efficiency in proteomic analysis by: 'Korea University selected Seer's new Proteograph ONE workflow as the foundation for this critical and forward-looking initiative so that they can unlock the full potential of proteomics in population-scale research,' said Omid Farokhzad, Chair and CEO of Seer. 'We're excited to help define a new generation of diagnostics that can transform how diseases like cancer are detected and managed around the world.' The study also employs Thermo Scientific's Orbitrap Astral MS—the industry's leading mass spectrometer for proteomic research. The Proteograph offerings combined with the Orbitrap Astral MS provide a deep, full-range plasma proteome analysis at faster speeds to enable critical breakthrough discoveries in large-population studies. 'When it comes to plasma proteomics studies such as this, the Orbitrap Astral MS and Proteograph ONE workflow provide a powerful solution to drive groundbreaking research,' said Dan Shine, senior vice president and president of analytical instruments, Thermo Fisher Scientific. 'We're proud to be a part of initiatives like this to enable earlier detection and help progress precision medicine.' The next-generation offerings mark a significant evolution of the Proteograph Product Suite, delivering the scale, speed, and efficiency required to make population-level proteomics both practical and accessible. The collaboration with Korea University exemplifies the real-world impact of this technology—demonstrating how deep, unbiased proteomic insights powered by Seer's platform can now inform large-scale studies, accelerate biomarker discovery, and drive the development of AI-enabled diagnostics that redefine precision medicine. About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer's Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer's robust and scalable workflow consistently reveals biological insights that others cannot. Seer's products are for research use only and are not intended for diagnostic procedures. For more information about Seer's differentiated approach and ongoing leadership in proteomics, visit Media Contact: Consort Partners [email protected] Investor Contact: Carrie Mendivil [email protected]
Yahoo
3 days ago
- Health
- Yahoo
Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer's new Proteograph ONE Assay to accelerate analysis and reduce costs, making large-scale studies feasible REDWOOD CITY, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, and Korea University, a leading research institution committed to innovation and global impact, today announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Relying on Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes. Seer's latest platform advances will allow deep, unbiased proteomic analysis of 20,000 plasma samples in less time and cost than has ever before been possible. These will include samples from 15,000 cancer patients and 5,000 healthy patients that will serve as controls, sourced from Korea's leading cancer institutions: Seoul National University Hospital, the National Cancer Center, and Samsung Medical Center. The three-year study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea, which supports ambitious, high-impact health research. 'We carefully evaluated multiple approaches to expand the dynamic range of the plasma proteome—including some attempting to replicate Seer's Proteograph platform—and Seer's assay stood out as the only solution capable of delivering the depth, scale, and, critically, reproducibility needed for this ambitious study,' said Professor Sang-Won Lee at the Center of Proteogenome Research (CPGR) of Korea University. 'The unique combination of Seer's latest platform and CPGR's proprietary dual online liquid chromatography technology gives us the ability to conduct population-scale research that would otherwise be prohibitively complex and slow. This collaboration represents a major step toward developing AI-powered diagnostics that could fundamentally improve how we detect and treat cancer in younger adults.' By leveraging the power of deep proteomic analysis, this study aims to catalyze a new wave of diagnostics that are more sensitive, scalable, and personalized—ultimately driving earlier interventions and improving survival outcomes in young adult cancer patients worldwide. Transformational Technology for Population-Scale Proteomics At the heart of the study is Seer's Proteograph ONE workflow, introduced this week at the 2025 American Society for Mass Spectrometry (ASMS) Conference in Baltimore, MD. The next-generation system dramatically increases scale and efficiency in proteomic analysis by: Processing 1,000+ samples per week per instrument Requiring only a single mass spectrometry injection per sample Completing 80-sample batches with <5 hours automated runtime Identifying up to 10 times more proteins than conventional mass spectrometry methods 'Korea University selected Seer's new Proteograph ONE workflow as the foundation for this critical and forward-looking initiative so that they can unlock the full potential of proteomics in population-scale research,' said Omid Farokhzad, Chair and CEO of Seer. 'We're excited to help define a new generation of diagnostics that can transform how diseases like cancer are detected and managed around the world.' The study also employs Thermo Scientific's Orbitrap Astral MS—the industry's leading mass spectrometer for proteomic research. The Proteograph offerings combined with the Orbitrap Astral MS provide a deep, full-range plasma proteome analysis at faster speeds to enable critical breakthrough discoveries in large-population studies. 'When it comes to plasma proteomics studies such as this, the Orbitrap Astral MS and Proteograph ONE workflow provide a powerful solution to drive groundbreaking research,' said Dan Shine, senior vice president and president of analytical instruments, Thermo Fisher Scientific. 'We're proud to be a part of initiatives like this to enable earlier detection and help progress precision medicine.' The next-generation offerings mark a significant evolution of the Proteograph Product Suite, delivering the scale, speed, and efficiency required to make population-level proteomics both practical and accessible. The collaboration with Korea University exemplifies the real-world impact of this technology—demonstrating how deep, unbiased proteomic insights powered by Seer's platform can now inform large-scale studies, accelerate biomarker discovery, and drive the development of AI-enabled diagnostics that redefine precision medicine. About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer's Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer's robust and scalable workflow consistently reveals biological insights that others cannot. Seer's products are for research use only and are not intended for diagnostic procedures. For more information about Seer's differentiated approach and ongoing leadership in proteomics, visit Media Contact:Consort Partnerspr@ Investor Contact:Carrie Mendivilinvestor@ in to access your portfolio
Yahoo
07-04-2025
- Business
- Yahoo
AGC Biologics Strengthens Single-Use Technology Network and Adds 5,000 L Vessels from Thermo Scientific to New Yokohama, Japan Facility
CDMO's new site introducing the most advanced and large-scale single-use bioreactors in the region YOKOHAMA, Japan & SEATTLE, April 07, 2025--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a strategic decision about the large-scale single-use technology it will use at its new Yokohama, Japan facility. The CDMO is introducing two 5,000 L Thermo Scientific DynaDrive Single-Use Bioreactors (S.U.B.), which makes the site one of the most advanced in Japan for large-scale mammalian-based biologics production, with GMP operations beginning in 2027. According to 2024 data from BDO Group's bioTRAK Database, single-use technology represents 51 percent of all mammalian bioreactor technology globally, outpacing the traditional stainless-steel alternative. Attributes driving this trend include fewer cleaning requirements, lower cost barrier to entry and timeline for setup, flexible configurations, scalability to meet changing product demands, and shorter clinical production timelines. AGC Biologics has the second largest global network of single-use manufacturing capacity by volume in the industry, according to bioTRAK. The new bioreactor technology ensures the company stays ahead of industry-wide demand for single-use systems. "The new Yokohama site is designed to utilize single-use bioreactors to offer large-scale GMP manufacturing. The cutting-edge technology from Thermo Scientific makes this one of the most advanced sites in Japan for large-scale manufacturing and further expands our robust global network of single-use manufacturing sites on three continents," said Christoph Winterhalter, Chief Business Officer, AGC Biologics. "This location offers the capabilities to meet the commercial needs of customers in Japan and Asia, as well as global customers seeking capacity using the latest technology." "Flexibility and the means to scale production cost-effectively is key for any developer of therapies today, and CDMOs need the best technology possible to help them accomplish that. The DynaDrive 5,000 L Single-Use Bioreactor delivers seamless scalability, exceptional flexibility, and superior process intensification capabilities – embodying best-in-class performance. AGC Biologics' new site in Yokohama will be a premier site in Japan for large-scale single-use technology thanks to our collaboration," said Daniella Cramp, Senior Vice President and President of Thermo Fisher Scientific's Bioproduction business. The new AGC Biologics Yokohama facility will offer support from initial process development work for early-phase projects to late-phase and commercial production. It will support mammalian expression, cell therapy, and messenger RNA (mRNA) drug products. The Yokohama facility is expected to help maximize operational and supply chain efficiencies across AGC Biologics' global network by adding another site in the region. The CDMO currently operates one site in Japan, its Chiba facility, offering mammalian expression and microbial fermentation services. AGC Biologics is a part of AGC Inc.'s Life Science Company. The Life Science company operates over 10 facilities worldwide focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more about AGC Biologics' global network of services for protein biologics and cell and gene therapies, please visit About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,800 Team Members worldwide. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit View source version on Contacts Media Contact Nick McDonaldAGC Biologicsnmcdonald@ AGC Inc. Media Contact info-pr@ Sign in to access your portfolio
Yahoo
30-03-2025
- Business
- Yahoo
Is Thermo Fisher Scientific (TMO) The Most Expensive Stock Insiders Are Dumping In March?
We recently published a list of . In this article, we are going to take a look at where Thermo Fisher Scientific Inc. (NYSE:TMO) stands against other most expensive stocks insiders are dumping in March. After being in the green for a few trading sessions, the broader market index slid 0.8% on Wednesday, and blue-chip companies declined 0.1%. The NASDAQ Composite was down 1.6% in the early afternoon. On Tuesday, Trump provided an update on tariffs, saying they will likely be more 'lenient than reciprocal,' suggesting a more relaxed approach, reports CNBC. As investors process daily market developments, uncertainty continues to impact the market. In these periods, insider trading often attracts attention, as purchases of company stock by executives may suggest confidence in the company's future. However, insider selling doesn't necessarily imply a lack of faith—it may be driven by personal financial needs or a desire for diversification. Executives frequently rely on pre-established plans, such as 10b5-1, to maintain transparency. While insider trading can provide useful insights, it should be evaluated in the context of a company's financial health, market trends, and industry changes. What are some of the most expensive stocks insiders have been selling this month so far? To find out, we used Insider Monkey's insider trading stock screener, focusing only on stocks where at least three insiders had sold shares in March. From there, we ranked the 20 stocks with the highest average price per share in times of sales. Our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds, focusing on insider trading and stock picks from hedge fund investor newsletters and conferences. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). With each stock, we note the average price per share of these sales and the stock's market capitalization. An engineer at a workbench surrounded by automotive parts, tools, and microchips. Market Capitalization: $194.04 billion Thermo Fisher Scientific Inc. (NYSE:TMO) provides a wide range of life sciences solutions, analytical instruments, diagnostics, laboratory products, and biopharma services globally. Its offerings include products for biological research, drug and vaccine production, clinical diagnostics, and laboratory research across various industries. The Waltham, Massachusetts-headquartered company operates under several brands such as Thermo Scientific, Invitrogen, and Applied Biosystems. For the full year 2024, Thermo Fisher (NYSE:TMO) disclosed revenue of $42.88 billion, flat compared to 2023. Full year GAAP diluted earnings per share (EPS) grew 7% to $16.53. In recent developments, Thermo Fisher (NYSE:TMO) launched the Thermo Scientific Vulcan Automated Lab, a system designed to improve productivity and yield, and reduce costs for semiconductor manufacturers. The solution aims to address the growing demand for advanced metrology data in semiconductor manufacturing as technologies become more complex. Marc N. Casper, CEO of Thermo Fisher, emphasized the company's expertise in electron microscopy and AI to help semiconductor manufacturers enhance efficiency. In March, three insiders, including the chairman and CEO, sold around $12.28 million worth of Thermo Fisher shares at an average price of $520.17 per share. The stock currently trades at $514.34 per share, having lost 1.13% year-to-date, and 9.58% over the past 12 months. Based on 18 Wall Street analysts' ratings, Thermo Fisher (NYSE:TMO) stock is a 'Strong Buy' with a price target of $662.00. According to TipRanks, the average price target represents a 28.71% upside from the latest price. Thermo Fisher (NYSE:TMO) is also one of the . Overall, TMO ranks 8th on our list of most expensive stocks insiders are dumping in March. While we acknowledge the potential of TMO our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TMO but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: and . Disclosure: None. This article is originally published at . Sign in to access your portfolio
